DCR

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 certainty unassessable+15%

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant